Ara
Toplam kayıt 4, listelenen: 1-4
Infectious side effects of baricitinib: A big data analysis based on VigiBase
(Elsevier B.V., 2023)
Dear Editor, Baricitinib (known as “Olumiant”), is an inhibitor of Janus- associated kinase 1 and 2 (JAK1 and JAK2) initially introduced for the treatment of rheumatoid arthritis (RA), and later for systemic lupus erythematosus ...
A multicenter, randomized, single-blind, 2-arm intervention study evaluating the adverse events and quality of life after irreversible electroporation for the ablation of localized low-intermediate risk prostate cancer. Reply.
(Wolters Kluwer Health, 2023)
To the Editor: We appreciate this opportunity toaddress the concerns in the comment by Jin et al on ourarticle,1evaluating the adverse events and quality of lifeafter irreversible electroporation (IRE) for the ablationof ...
Focal therapy for prostate cancer: Evolutionary parallels to breast cancer treatment. Letter.
(Wolters Kluwer Health, 2023)
To the Editor:We read with great interest the recentmanuscript by Labbate et al reviewing the develop-ment of focal therapy in breast and prostate cancer(PCa).1Breast focal therapy (bFT) represents a suc-cessful model for ...
Attaching a stigma to the LGBTQI plus community should be avoided during the monkeypox epidemic
(Wiley, 2023)
Dear Editor,An outbreak of monkeypox, a rare zoonotic disease caused by anorthopoxvirus, is currently ongoing and has spread so far to morethan 20 countries, mostly affecting Europe, the Americas, Australia,and Israel, ...